Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SFCC provides outsourced drug development research services -- Ignore unavailable to you. Want to Upgrade?

To: xstuckey who wrote (10)	11/18/2001 5:10:18 PM
From: Skywatcher	Respond to of 29

been on vacation....guess they thought it couldn't get worse at this price....dickheads....getting very greedy since they diluted all of us so much already. CC

To: xstuckey who wrote (10)	5/7/2002 2:40:45 PM
From: Skywatcher	Read Replies (1) \| Respond to of 29

SFBC International's Revenues and Net Income Set New First Quarter Records Net Income Up 75 Percent on a 45 Percent Increase in Revenues MIAMI--(BUSINESS WIRE)--May 7, 2002--SFBC International, Inc. (Nasdaq:SFCC - news) a provider of specialized, outsourced drug development research services to the pharmaceutical and biotechnology industries, today announced record first quarter sales and net income for the period ended March 31, 2002. Revenues were $9.6 million up 45 percent from $6.6 million in the first quarter of 2001. Net income of $1.3 million compared to $760,832 in the year earlier three-month period, registered a 75 percent improvement over the previous record for a first quarter. Reflecting both last summer's exercise of warrants and last December's sale of two million shares, the number of average shares outstanding on a fully diluted basis during the first quarter of this year was nearly 100 percent more than the same period last year. Earnings per fully diluted share of $0.18 for the first three months of 2002 exceeded the consensus of analysts' first quarter earnings estimates. The 2002 revenues and net income were a quarterly record. All of the Company's business units were profitable and contributed to this growth. Arnold Hantman, Chief Executive Officer of SFBC International, stated, "Our first quarter results were in line with expectations and we were pleased with the integration progress of Anapharm. With the addition of the growing and complementary operations of Anapharm, as well as the strength being shown by our core business we look for net income to more than double for 2002. Finally with $16.0 million of cash on hand, our growth could be further enhanced by additional acquisitions." However...the incredibly greedy DILUTION is really hurting us still.....massive increase in revenues and STILL LOWER EPS......damn it CC